Clearside Biomedical, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021
August 10, 2021 at 04:17 pm EDT
Share
Clearside Biomedical, Inc. announced earnings results for the second quarter ended June 30, 2021. For the second quarter, the company announced operating loss was USD 6.096 million compared to USD 5.557 million a year ago. Net loss was USD 6.095 million compared to USD 5.754 million a year ago. Basic loss per share from continuing operations was USD 0.11 compared to USD 0.13 a year ago. For the half year, operating loss was USD 14.445 million compared to USD 8.393 million a year ago. Net loss was USD 13.446 million compared to USD 8.665 million a year ago. Basic loss per share from continuing operations was USD 0.23 compared to USD 0.19 a year ago.
Clearside Biomedical, Inc. is a biopharmaceutical company focused on the delivery of therapies to the back of the eye through the suprachoroidal space (SCS). The Company's SCS injection platform, utilizing its patented SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. The Company is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector. The Company's lead program, CLS-AX (axitinib injectable suspension), for the treatment of neovascular age-related macular degeneration (wet AMD), is in Phase 2b clinical testing. It developed and gained approval for its product, XIPERE (triamcinolone acetonide injectable suspension) for suprachoroidal use, which is available in the United States through a commercial partner.
CLEARSIDE BIOMEDICAL, INC. 
